OP136 Provision Of A Chimeric Antigen Receptor T-Cell Program: A Rapid Review
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Technology Assessment in Health Care"
DOI: 10.1017/s0266462319001648
Abstract: Introduction The recent European Medicines Agency (EMA) approval of chimeric antigen receptor (CAR) T-cell therapies, axicabtagene ciloleucel and tisagenlecleucel, means the imminent arrival of health technology assessment (HTA) submissions to HTA agencies. HTA requires identification… read more here.
Keywords: rapid review; cell; car cell; cell program ... See more keywords